ATE293992T1 - Verfahren zur behandlung von allergischen lungenkrankheiten - Google Patents

Verfahren zur behandlung von allergischen lungenkrankheiten

Info

Publication number
ATE293992T1
ATE293992T1 AT97945544T AT97945544T ATE293992T1 AT E293992 T1 ATE293992 T1 AT E293992T1 AT 97945544 T AT97945544 T AT 97945544T AT 97945544 T AT97945544 T AT 97945544T AT E293992 T1 ATE293992 T1 AT E293992T1
Authority
AT
Austria
Prior art keywords
antigen
asthma
disease
presenting cells
host
Prior art date
Application number
AT97945544T
Other languages
German (de)
English (en)
Inventor
Dennis A Carson
Eyal Raz
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24916669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE293992T1 publication Critical patent/ATE293992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
AT97945544T 1996-10-04 1997-10-06 Verfahren zur behandlung von allergischen lungenkrankheiten ATE293992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/725,968 US5849719A (en) 1993-08-26 1996-10-04 Method for treating allergic lung disease
PCT/US1997/018084 WO1998014210A1 (en) 1996-10-04 1997-10-06 Method for treating allergic lung disease

Publications (1)

Publication Number Publication Date
ATE293992T1 true ATE293992T1 (de) 2005-05-15

Family

ID=24916669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945544T ATE293992T1 (de) 1996-10-04 1997-10-06 Verfahren zur behandlung von allergischen lungenkrankheiten

Country Status (8)

Country Link
US (4) US5849719A (enExample)
EP (1) EP0935470B1 (enExample)
JP (1) JP2001503741A (enExample)
AT (1) ATE293992T1 (enExample)
AU (1) AU740600B2 (enExample)
CA (1) CA2267675A1 (enExample)
DE (1) DE69733145T2 (enExample)
WO (1) WO1998014210A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
KR20010020570A (ko) 1997-06-30 2001-03-15 자끄 사비나 다세포 진핵 생물 세포중으로 개선된 핵산 전달방법 및이를 위한 콤비네이션
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
EP1872786A1 (en) * 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
AU1631399A (en) 1997-12-19 1999-07-12 Beth Israel Deaconess Medical Center Methods and compositions for inhibiting tumor cell growth
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
EP1078053B1 (en) * 1998-05-14 2005-09-28 Coley Pharmaceutical GmbH METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
ATE335510T1 (de) * 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US7244714B1 (en) 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1104456A1 (en) * 1998-08-10 2001-06-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
JP3707303B2 (ja) * 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2001227889A1 (en) * 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
WO2001094419A2 (en) * 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
US7534772B2 (en) 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AU2002231336B2 (en) * 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
AU2002345847B2 (en) 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
JP4607452B2 (ja) * 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20040248837A1 (en) * 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1575977E (pt) * 2002-12-23 2009-12-15 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
BRPI0606445A2 (pt) 2005-01-20 2009-03-10 Biomarck Pharmaceuticals Ltd inibidores de hipersecreÇço de mucina e mÉtodos de uso
CA2598806A1 (en) 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2007421A2 (en) * 2005-03-04 2008-12-31 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients.
DE602006015963D1 (de) 2005-07-01 2010-09-16 Index Pharmaceuticals Ab Immunstimulatorisches verfahren
DK2179737T3 (da) 2005-07-01 2013-11-11 Index Pharmaceuticals Ab Modulering af respons på steroider
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
KR101599894B1 (ko) * 2006-07-26 2016-03-04 바이오마크 파마슈티칼스 리미티드 염증 매개물질의 분비를 감쇄시키는 방법 및 그에 유용한 펩티드
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
US9717657B2 (en) 2012-10-24 2017-08-01 Amy Dukoff Composition and method of using medicament for endodontic irrigation, stem cell preparations and tissue regeneration
CN114302706A (zh) 2019-06-17 2022-04-08 碧奥马尔克制药有限公司 治疗葡萄膜炎的肽及其使用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228795A (en) * 1977-03-08 1980-10-21 Babington Robert S Apparatus for producing finely divided liquid spray
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de) * 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
JPH09501936A (ja) * 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0983289A4 (en) 1997-05-19 2001-04-25 Merck & Co Inc OLIGONUCLEOTIDE AIDS
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP1872786A1 (en) * 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001055341A2 (en) * 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
JP4607452B2 (ja) * 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法

Also Published As

Publication number Publication date
JP2001503741A (ja) 2001-03-21
AU740600B2 (en) 2001-11-08
US5849719A (en) 1998-12-15
US6426336B1 (en) 2002-07-30
US6174872B1 (en) 2001-01-16
CA2267675A1 (en) 1998-04-09
US6951845B2 (en) 2005-10-04
EP0935470B1 (en) 2005-04-27
DE69733145D1 (de) 2005-06-02
DE69733145T2 (de) 2006-03-02
US20030027782A1 (en) 2003-02-06
WO1998014210A1 (en) 1998-04-09
EP0935470A1 (en) 1999-08-18
AU4671997A (en) 1998-04-24

Similar Documents

Publication Publication Date Title
ATE293992T1 (de) Verfahren zur behandlung von allergischen lungenkrankheiten
ATE353657T1 (de) Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
DE69534374D1 (de) Methoden und zubehör zur immunisierung von wirtsorganismen durch verabreichung nackter polynucleotide , welche für antigene peptide codieren
DE69332518D1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE3806565A1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
BRPI9912177B8 (pt) epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptídeo sintéticos, imunógenos de peptídeo e método para a produção dos mesmos
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
ATE291628T1 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
FI973120A7 (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
GRIFFIN et al. ULTRASONIC MOVEMENT OF CORTISOL INTO PIG TISSUES I. MOVEMENT INTO SKELETAL MUSCLE
IL174902A0 (en) Multispecific deimmunized cd3-binders
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
Scicchitano et al. Contribution of intraperitoneal immunization to the local immune response in the respiratory tract of sheep
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
PT910407E (pt) Metodo e composicao para modificar a conformacao de antigenios multi-epitopicos de modo a iniciar uma resposta imunitaria
DK0433088T3 (da) Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties